Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1844
Source ID: NCT01226966
Associated Drug: Liraglutide
Title: Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes
Acronym: EVIDENCE
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: liraglutide
Outcome Measures: Primary: Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%, Month 24 | Secondary: Change in HbA1c at month 3, Month 0, Month 3|Change in HbA1c at month 6, Month 0, Month 6|Change in HbA1c at month 12, Month 0, Month 12|Change in HbA1c at month 18, Month 0, Month 18|Change in HbA1c at month 24, Month 0, Month 24|Change in fasting plasma glucose (FPG) at month 3, Month 0, Month 3|Change in fasting plasma glucose (FPG) at month 6, Month 0, Month 6|Change in fasting plasma glucose (FPG) at month 12, Month 0, Month 12|Change in fasting plasma glucose (FPG) at month 18, Month 0, Month 18|Change in fasting plasma glucose (FPG) at month 24, Month 0, Month 24|Change in Body Weight at Month 3, Month 0, Month 3|Change in Body Weight at Month 6, Month 0, Month 6|Change in Body Weight at Month 12, Month 0, Month 12|Change in Body Weight at Month 18, Month 0, Month 18|Change in Body Weight at Month 24, Month 0, Month 24
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 3152
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2010-09
Completion Date: 2013-11
Results First Posted:
Last Update Posted: 2017-02-13
Locations: Novo Nordisk Investigational Site, Paris La défense cedex, 92932, France
URL: https://clinicaltrials.gov/show/NCT01226966

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress